NEW YORK, Aug 27 – Incyte and CV Therapeutics said Monday they had agreed to work together to study the role genes play in heart disease, expanding a joint research effort that began in 1998.

Under the terms of the new agreement, the companies, both of Palo Alto, Calif., said they would focus on pinpointing genes associated with atherosclerosis and coronary artery disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.